^
Association details:
| Biomarker: | FGFR1 overexpression |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
The impact of FGFR1 and FRS2a expression on sorafenib treatment in metastatic renal cell carcinoma
Excerpt:
In a prospective phase II trial, untreated patients with metastatic clear cell RCC were randomly allocated to receive sorafenib....Our data indicates that increased expression of FGFR1 and FRS2α is associated with a worse PFS on first-line sorafenib treatment.
DOI:
10.1186/s12885-015-1302-1
Trial ID:
